Gut & Digestive

544 Papers, 30 Years, One Lab — The Healing Peptide with the Most Research and the Least Independent Evidence

Alpha-MSH's Anti-Inflammatory Fragment — And It May Work Completely Differently Than Everyone Thinks

The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.

NOT a Peptide — A Synthetic Heterocyclic Amine. Zero Human Clinical Trials. The Most Compelling In Vitro Dopaminergic Neuroprotective Profile in the Nootropic Space. Also a MAO-A Inhibitor (IC50 = 1 μM) With Tyramine Reaction and Serotonin Syndrome Risk. Also a Photosensitizer With UV-Activated DNA Damage Potential. The Most Dangerous Safety Profile of Any Nootropic in This Book.

Engineered to Not Be EPO. Proven to Regenerate Nerves in Humans. WADA Banned Anyway. And the Company That Made It No Longer Exists.

Novo Nordisk's Long-Acting Amylin Analogue. The First New Mechanism in Obesity Pharmacology Since GLP-1. Phase 3 REDEFINE 1 (NEJM, June 2025): CagriSema = 22.7% Weight Loss — Among the Highest Ever Reported for Obesity Medication. Cagrilintide Monotherapy = 11.8% at 68 Weeks. Phase 3 Trials Completed. NDA Filing Expected Q1 2026. Not Yet Approved. Community Access Through Research Vendors.

GlaxoSmithKline Halted Their Own Drug in 2007 Because It Caused Cancer in Every Animal Species They Tested. The Community Is Still Using It. The Drug Worked. That Is the Entire Problem.

More Clinical Trial Data Than Almost Anything in This Book. Approved in Over 40 Countries. The Largest Independent RCT Failed Its Primary Endpoint. Every Major Positive Trial Has the Manufacturer's Name in the Author List. Cochrane Says: Low to Very Low Evidence.

The Most Prescribed GH Secretagogue Combination in Clinical Practice — and the One Decision That Changes Everything: DAC or No DAC.

MIC injection tradition originates from lipotropic injection protocols developed in bariatric and weight loss medicine

The Only Senolytic With Real Human Trial Data. Tested at the Mayo Clinic. Proven to Clear Senescent Cells in Humans. Dasatinib Is a Chemotherapy Drug. The Community Is Using It Without Prescriptions, ECGs, or Drug Interaction Screens.

Reported to Be 10 Million Times More Potent Than BDNF. The Foundational Mechanistic Data Is Under a Research Integrity Cloud. The Clinical Prodrug Failed Phase 2/3. The Community Uses It Anyway.

Isolated 1977. Named for Sleep. 40+ Years of Research. No Gene Found. No Specific Receptor Identified. Half-Life 15 Minutes In Vitro — Yet Produces Multi-Night Effects. Studied for Sleep, Stress, Alcohol Withdrawal, Opiate Withdrawal, Neuroprotection, and Longevity. The Most Mechanistically Mysterious Compound in This Book.

The World's Best-Selling Senolytic Supplement. One Landmark Mouse Study. One ITP Failure. Multiple Human Trials Running for Years With No Published Senolytic Endpoint Data. The Bioavailability Problem Nobody in the Marketing Ecosystem Discusses.

Zero Published Human RCTs for the Injectable Route. Every Protocol is Extrapolated from Topical and Animal Data. The Anela Protocol: The Community Standard Defined. ISR Management: Why 3mL/50mg is the Standard Dilution. Copper Accumulation Risk on Long Cycles. The Systemic Healing Signal: Animal Evidence That Injected GHK-Cu Heals at Remote Sites. The Active Malignancy Hard Stop. Reconstitution Guide. Stacking with BPC-157 and TB-500 in the GLOW Protocol.

The Original GHRP — Discovered 12 Years Before the Receptor It Activates Was Named. The Compound That Proved the Ghrelin System Existed Before Ghrelin Was Found. Why Every Subsequent GHRP Was Designed to Fix GHRP-6's Problems. The Hunger That Arrives in 20 Minutes. Cortisol and Prolactin: How Much, Why It Matters, When to Care. The Unexpected Cytoprotective Signal Via CD36. Why Some Bulkers Prefer It Over Ipamorelin on Purpose.

FDA-Approved for Fertility and Male Hypogonadism. The Most Important Hormone in Post-Cycle Therapy. The Active Ingredient in the Simeons 500-Calorie Diet — a Fraud With Its Own FDA Warning. WADA S2 Banned. A Tumor Marker. Three Completely Different Identities in One Glycoprotein.

Designed as a Research Tool to Bypass IGFBP Regulation. ~100-Fold Reduced Binding-Protein Affinity. 20-30 Hour Half-Life vs IGF-1's 10-15 Minutes. The Most Potent IGF-1 Analog Available. No Controlled Human Trial for Body Composition. No Tumor Selectivity. WADA S2 Banned. A Compound Whose Full Cancer Risk Is Genuinely Unknown.

40+ Years of Russian Research. 500+ Publications. One Institution. The Most Concentrated Single-Lab Provenance of Any Compound Class in This Book. Vladimir Khavinson (1946-2024) and the St. Petersburg Institute of Bioregulation and Gerontology. The Epigenetic Chromatin Mechanism. The Cytomax vs Cytogen Distinction. The 6-to-8-Year Mortality Study. The 2025 Independent Replication That Changed the Evidence Conversation. 14 Organ-Specific Bioregulators — Their Sequences, Targets, Evidence, and Protocols.

NOT a Peptide — An Amino Acid Quaternary Ammonium Compound. The Most Commercially Overstated Compound in This Book. Genuine Grade B Evidence for Neuropathy (ALCAR), Peripheral Artery Disease (PLCAR), Muscle Recovery (LCLT), Male Infertility (L-Carnitine), and Post-MI Cardiac Outcomes. The TMAO Safety Question. Why Using the Wrong Form Explains Half the Negative Trials. FDA-Approved for Dialysis-Related Carnitine Deficiency.

Every Cell Makes It. Every Major Disease Depletes It. Oral Supplementation Below 1% Bioavailability in Standard Form. IV Delivery With Documented Fatalities. A Billion-Dollar Skin Whitening Industry Built on Mixed Evidence. The Precursor Strategy That Outperforms the Molecule Itself.

NOT a Single Molecule — A Compounded Formulation That Varies by Pharmacy. The Most Commercially Prominent Injectable in Weight Loss Clinics. Zero RCTs for the Combination as a Weight Loss Intervention. Strong Component-Level Evidence for Inositol in PCOS/Insulin Resistance (Oral). Legitimate Bioavailability Advantage for B12 Injection in Deficiency Only. The Injection That Is More Psychologically Than Pharmacologically Distinctive.

⚠ NAMING COLLISION: 'Lipo-C' is used for TWO completely different products — this chapter covers the compounded MIC+L-Carnitine+B-vitamins lipotropic injection. Liposomal Vitamin C (a separate oral supplement also called 'Lipo-C') is covered in a separate chapter. Read Section 1 before proceeding. Lipo-B Extended: Adds L-Carnitine, Thiamine (B1), and Dexpanthenol (B5) to the Lipo-B MIC+B12 base. Zero RCTs for the combination. L-Carnitine Injectable Dose is 100-200x Below Oral Therapeutic Doses. Mechanistically Coherent. Clinically Unproven.

The Only Human Cathelicidin. Antimicrobial, Anti-Biofilm, Pro-Angiogenic, Immunomodulatory, Wound-Healing. Phase IIb Clinical Evidence in Chronic Wounds. Overexpressed in Rosacea, Ovarian Cancer, Breast Cancer, Lung Cancer, Melanoma. Tumor-Suppressive in Colon and Gastric Cancer. The Most Contextually Bidirectional Compound in This Book. Vitamin D Is Its Most Important Natural Inducer.

The World's First Approved Dual GCG/GLP-1 Receptor Agonist. NMPA-Approved in China June 2025 for Obesity. Second NMPA Approval September 2025 for T2D. Phase 3 T2D Data Published Back-to-Back in Nature December 2025. Originally Eli Lilly's LY3305677 — Licensed to Innovent Biologics for China Development. No FDA Submission as of Mid-2026. The Drug That Is Simultaneously Approved, Unavailable, and a Research Chemical Depending on Where You Are.

The TAME Trial: The First FDA-Recognized Study to Use 'Aging' as a Drug Indication. The Bannister Study: Diabetics on Metformin Outlive Non-Diabetics. The 2024 Cell Primate Paper: 6.1-Year Brain Aging Regression. The Exercise Controversy: Metformin Blunts the Mitochondrial Benefits of Training. B12 Depletion: The Most Important Long-Term Safety Issue. Metformin vs Rapamycin: The Same mTOR Pathway, Different Entry Points. Who Benefits Most. Who Shouldn't Use It.

The Only Oral Compound in This Book That Reliably Raises GH and IGF-1. GHSR-1a Agonist: Not a SARM. The Merck Story: Six Indications, No NDA, Program Discontinued. IGF-1 Goes Up. Fat-Free Mass Goes Up. Strength Doesn't Follow. Glucose Does Go Up. Appetite Definitely Goes Up. The CHF Signal in Elderly Patients. FDA October 2024 PCAC: No Compounding. WADA S2. The Water Weight Trap. Why Sleep Quality Is the Most Reliable Benefit. The Community's Most Misunderstood Compound.

The Drug That Was Going to Treat Leaky Gut and Celiac Disease — And How the Phase 3 Trial Ended. What Zonulin Actually Is and Why Tight Junction Regulation Is Hard to Measure. Four Phase 2 RCTs: Symptom Improvement With Gluten Challenge. The Phase 3 Discontinuation in 2022. The N-Acetyl Modification That Limitless Sells: What It Adds and What It Doesn’t Change. How This Differs From BPC-157 and KPV in the Gut Stack.

ACTH Fragment Without the Cortisol Effect. Russia's Premier Nootropic-Neuroprotective Peptide. Approved for Stroke, Encephalopathy, Optic Nerve Atrophy, Cognitive Disorders. BDNF Upregulation 50-300% in Hippocampus and Frontal Cortex. Default Mode Network Changes by fMRI. 71% vs 41% Memory Test Accuracy in Fatigued Volunteers. Half-Life Extended from 3-5 Minutes (Semax) to 4-6 Hours (MASA) by N-Acetyl and Amidate Modifications.

This addendum expands the NAD+ chapter with a dedicated section on subcutaneous injectable NAD+ — covering pharmacokinetics, why SubQ differs from oral precursors and IV infusion, reconstitution from lyophilised vials, injection technique, dose titration, side effect management, and the honest evidence comparison with oral NMN/NR and IV administration.

FDA-Approved at 50 mg for Opioid and Alcohol Use Disorder Since 1984. Off-Label at 1.5-4.5 mg (LDN) — Two Completely Different Mechanisms at Two Completely Different Doses. TLR4 Blockade on Microglia. The Endorphin Rebound. A Lancet Rheumatology RCT in 2024. An Evidence Base Growing Faster Than Pharma Has Any Reason to Fund. The Most Favorably Tolerated Prescription Drug in Its Evidence Literature.

The Compound That Is 1,000x More Potent Than Piracetam by Weight. The Prodrug Whose Active Metabolite Is Endogenous to the Human Brain. Phase III Clinical Trials Exist — In Russian. Russian OTC Approval Since 2006 — Based on Real Trials That Western Evidence-Based Reviewers Cannot Read. Why It Is Not a Racetam Despite What Everyone Says. Cycloprolylglycine: The Metabolite That Does the Work. Enhanced Dreams as a Pharmacological Signal. The Dose Ceiling That Most Community Users Ignore.

The First True Oral GLP-1: Take It Anytime, With or Without Food, No Injection. ATTAIN-1 (NEJM 2025; n=3,127; 72 Weeks): -11.2% Body Weight at 36mg. Why Small Molecule Matters: The Chemistry That Makes This Pill Possible When No Peptide Could Be. Orforglipron vs Oral Semaglutide vs Injectable GLP-1s: The Efficacy-Accessibility Trade-Off. ATTAIN-MAINTAIN: It Maintains Weight Loss After Switching Off Wegovy and Zepbound. Why This Compound Changes Who Gets GLP-1 Therapy.

The 7-Amino-Acid Antidepressant That Works in 4 Days Instead of 4 Weeks. TREK-1: The Potassium Channel That Keeps You Depressed. IC50 of 0.12 nM — 333x More Potent Than Its Parent Spadin. Duration Extended to 23 Hours vs 7 Hours. Hippocampal Neurogenesis in 4 Days. The Same One French Research Group Since 2010. Zero Human Trials. A Novel Mechanism That Bypasses the Serotonin Transporter Entirely.

28.7% Weight Loss in Phase 3. The Most Effective Weight Loss Drug Ever Trialed. Not Approved. Not Available by Prescription. The Community Is Already Using It. And It Is Not the Same Drug as Tirzepatide.

The Drug That Extended Rat Lifespan in 1988 and Still Fascinates the Longevity Community. Irreversible MAO-B Inhibitor. Dopamine Preservation. BDNF Upregulation. The DATATOP Trial: Symptomatic Effect, Not Neuroprotection — The Distinction That Matters. The Amphetamine Metabolites: L-Enantiomers Only — What That Means Clinically. Low-Dose Community Protocols (1-5 mg Every Few Days). Why High-Dose Loses MAO-B Selectivity and What Happens Then. Selegiline vs Rasagiline. The Cheese Reaction: When It Applies and When It Doesn't.

The Only FDA-Approved Mitochondrial Therapeutic. Most Clinical Trials Failed. The Basic Science Is Compelling. All Three of These Things Are True Simultaneously.

GLOW Stack is the Wolverine Stack with GHK-Cu added

is not evidence quality — it is scope appropriateness

KLOW is mechanistically the most comprehensive tissue repair protocol in this book — four non-overlapping mechanisms covering angiogenesis, cell migration, ECM remodeling, and inflammatory suppression simultaneously. The tension: comprehensiveness is not the same as superiority. Adding a fourth compound means: more injections (or more complex blended vial formulation); more copper accumulation risk on extended cycles (GHK-Cu); more cost; and more moving parts when something doesn't work as expected. For many users, GLOW already covers their needs; KLOW is the right choice when the inflammatory dimension or gut protection is a specific priority. The chapter exists to clarify when KLOW is worth the additional complexity.

Most Widely Used Peptide Healing Combination in Community History

The Glucagon Rehabilitation Story. Phase 2 MASH (NEJM July 2024): 62% MASH Resolution vs 14% Placebo. Phase 3 SYNCHRONIZE-1 (April 2026): -16.6% Weight Loss at 76 Weeks. FDA Breakthrough Therapy for MASH September 2024. LIVERAGE Phase 3 MASH Ongoing. Why Glucagon in Metabolic Disease? The GLP-1 + GCGR Advantage Over GLP-1 + GIPR for Liver Disease. The Most Important Obesity Drug for MASH Patients That Nobody in the Community Has Heard Of.

NOT a Peptide — An Oral Small Molecule. Originally Developed for Alzheimer's and Parkinson's. Weight Loss Discovered as Incidental Finding. Lancet Phase 2b: 10.6% Body Weight Loss at 0.5mg (vs 2.0% Placebo). The Same +7-8 bpm Heart Rate Increase That Killed Sibutramine. The Tesomet Solution: Add a Beta-Blocker. Mexican Approval 2023. Phase 3 Ongoing. Absolute Contraindication with SSRIs and MAOIs.

Approved in 37+ Countries. The Most Extensively Studied Thymic Peptide in Clinical Medicine. 30+ RCTs. 11,000+ Subjects. HBeAg Seroconversion RR 2.31. A Positive Sepsis Trial in 2013 Followed by a Definitive Negative Phase 3 in 2025. The US Regulatory Rollercoaster: Category 2 (2023) → Nomination Withdrawn (2024) → Pending PCAC Review (2026). Immunomodulator, Not Immunostimulant — A Critical Distinction.

The Only Thymic Hormone That Requires a Metal Cofactor. Biologically Inactive Without Zinc. The Most Important Clinical Point: Zinc Deficiency Causes Functional Thymulin Deficiency — And Zinc Supplementation Restores It. One Human Interventional Study from 1982. Extensive Animal Evidence. The Chapter That Is Also a Zinc Education.

The Most Physiologically Broad Compound in This Book. 28 Amino Acids. Every System in the Body. VPAC1 and VPAC2. The 90-Second Half-Life Problem That Blocked IV Use. How Intranasal Administration Changed Everything. Dr. Shoemaker's CIRS Protocol: 300+ Physicians, 90%+ Symptom Reduction. The Long-COVID Connection. Aviptadil COVID ARDS Trials. The Mast Cell / MCAS Intersection. Why the Community Uses It and What the Evidence Actually Shows.